Chronic Myeloid Leukemia Epidemiology Forecast

Key Highlights

 

• As per the study Kiyotaka Yamazaki et al. (2020), Chronic Myeloid Leukemia is a myeloproliferative blood cancer, with an annual incidence in Japan of 0.5 cases per 100,000 population.

 

• According to NICE-UK, the annual incidence of Chronic Myeloid Leukemia is 4.2 cases per 100,000. In addition to that, Chronic Myeloid Leukemia represents only 5% of all childhood leukemia. It is also reported that 85-90% of patients are diagnosed in the chronic phase.

 

• Chronic Myeloid Leukemia epidemiology is segmented as Total Incident Cases of Chronic Myeloid Leukemia, Total Symptomatic Cases of Chronic Myeloid Leukemia, Cases of Chronic Myeloid Leukemia by Phases (Chronic, Accelerated, and Blast), Age-specific Cases of Chronic Myeloid Leukemia, and Mutation-specific Cases of Chronic Myeloid Leukemia] in the Chronic Myeloid Leukemia epidemiology report.

 

Request for unlocking of Chronic Myeloid Leukemia Epidemiology

 

DelveInsight's ‘Chronic Myeloid Leukemia Epidemiology Forecast — 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Chronic Myeloid Leukemia epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 

Study Period: 2021-2034

 

Chronic Myeloid Leukemia Epidemiology Disease Understanding

The DelveInsight’s Chronic Myeloid Leukemia market report gives a thorough understanding of Chronic Myeloid Leukemia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Chronic Myeloid Leukemia is also known as chronic myelogenous leukemia. It's a type of cancer that starts in certain blood-forming cells of the bone marrow. Chronic Myeloid Leukemia is a fairly slow growing leukemia, but it can change into a fast-growing acute leukemia that's hard to treat. The phases of Chronic Myeloid Leukemia are based on the number of immature white blood cells that are seen in the blood or bone marrow. The three phases of Chronic Myeloid Leukemia includes Chronic phase Chronic Myeloid Leukemia, Accelerated phase Chronic Myeloid Leukemia, and Blast phase Chronic Myeloid Leukemia.

 

People who have Chronic Myeloid Leukemia may not have any symptoms at first. Often, patients learn they have Chronic Myeloid Leukemia after a routine physical exam or a blood test. Chronic Myeloid Leukemia signs and symptoms tend to develop gradually which includes Weakness, Fatigue, Shortness of breath during basic everyday activities, Unexplained weight loss etc. Moreover, a shortage of normal white blood cells can increase a Chronic Myeloid Leukemia patient’s risk of infection, and a shortage of platelets can lead to excessive bruising or bleeding. Symptoms may also occur because Chronic Myeloid Leukemia cells collect in organs such as the spleen.

 

Chronic Myeloid Leukemia Diagnosis

There are certain tests that are used to diagnose Chronic Myeloid Leukemia which includes, Complete Blood Count (CBC) with Differential, this test is used to measure the number red blood cells, white blood cells and platelets in a sample of blood. Bone Marrow Aspiration and Biopsy, these tests are used to examine bone marrow cells to find abnormalities, and are generally done at the same time. The sample is usually taken from the patient’s hip bone after medicine has been given to numb the skin. Quantitative Polymerase Chain Reaction (qPCR) is the most sensitive test that detects and measures the quantity of the BCR-ABL1 gene in blood or bone marrow samples. It can detect very small amounts of the BCR-ABL1 gene to a level of one Chronic Myeloid Leukemia cell in a background of 100,000 to 1,000,000 normal cells.

 

Chronic Myeloid Leukemia Epidemiology

The Chronic Myeloid Leukemia epidemiology section provides insights about historical and current Chronic Myeloid Leukemia patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

 

• As per the study Kiyotaka Yamazaki et al. (2020), Chronic Myeloid Leukemia is a myeloproliferative blood cancer, with an annual incidence in Japan of 0.5 cases per 100,000 population.

 

• According to NICE-UK, the annual incidence of Chronic Myeloid Leukemia is 4.2 cases per 100,000. In addition to that, Chronic Myeloid Leukemia represents only 5% of all childhood leukemia. It is also reported that 85-90% of patients are diagnosed in the chronic phase.

 

• The disease epidemiology covered in the report provides historical as well as forecasted Chronic Myeloid Leukemia epidemiology [segmented as Total Incident Cases of Chronic Myeloid Leukemia, Total Symptomatic Cases of Chronic Myeloid Leukemia, Cases of Chronic Myeloid Leukemia by Phases (Chronic, Accelerated, and Blast), Age-specific Cases of Chronic Myeloid Leukemia, and Mutation-specific Cases of Chronic Myeloid Leukemia] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

 

Country Wise- Chronic Myeloid Leukemia Epidemiology

This section provides glimpse of the Chronic Myeloid Leukemia epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

KOL- Views

To keep up with the current Chronic Myeloid Leukemia patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Chronic Myeloid Leukemia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

 

Scope of the Chronic Myeloid Leukemia Epidemiology Report

• The report covers the descriptive overview of Chronic Myeloid Leukemia, explaining their causes, symptoms, pathophysiology, and genetic basis
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan
• The report assesses the disease risk and burden and highlights the unmet needs of Chronic Myeloid Leukemia
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Chronic Myeloid Leukemia, Total Symptomatic Cases of Chronic Myeloid Leukemia, Cases of Chronic Myeloid Leukemia by Phases (Chronic, Accelerated, and Blast), Age-specific Cases of Chronic Myeloid Leukemia, and Mutation-specific Cases of Chronic Myeloid Leukemia

 

Chronic Myeloid Leukemia Epidemiology Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Myeloid Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Myeloid Leukemia
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Learn how the therapeutic market will evolve and grow in the coming years: Chronic Myeloid Leukemia Market
 

Chronic Myeloid Leukemia Report Insights

• Patient Population
• Therapeutic Approaches

 

Chronic Myeloid Leukemia Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Chronic Myeloid Leukemia Epidemiology Segmentation

 

Chronic Myeloid Leukemia Report Assessment

• Disease Understanding
• Current Diagosis Practices and Guidelines
• Epidemiology Trends

 

Key Questions

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Chronic Myeloid Leukemia?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Chronic Myeloid Leukemia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Chronic Myeloid Leukemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Chronic Myeloid Leukemia?
• Out of all 7MM countries, which country would have the highest incident population of Chronic Myeloid Leukemia during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

 

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Chronic Myeloid Leukemia Disease market
• To understand the future market competition in the Chronic Myeloid Leukemia Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Chronic Myeloid Leukemia Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Chronic Myeloid Leukemia Disease market
• To understand the future market competition in the Chronic Myeloid Leukemia Disease market